RNA splicing dysregulation and the hallmarks of cancer

RK Bradley, O Anczuków - Nature Reviews Cancer, 2023 - nature.com
Dysregulated RNA splicing is a molecular feature that characterizes almost all tumour types.
Cancer-associated splicing alterations arise from both recurrent mutations and altered …

Protein synthesis control in cancer: selectivity and therapeutic targeting

JR Kovalski, D Kuzuoglu‐Ozturk, D Ruggero - The EMBO Journal, 2022 - embopress.org
Translational control of mRNAs is a point of convergence for many oncogenic signals
through which cancer cells tune protein expression in tumorigenesis. Cancer cells rely on …

[HTML][HTML] m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis

M Cieśla, PCT Ngoc, S Muthukumar, G Todisco… - Molecular Cell, 2023 - cell.com
SF3B1 is the most mutated splicing factor (SF) in myelodysplastic syndromes (MDSs), which
are clonal hematopoietic disorders with variable risk of leukemic transformation. Although …

METTL3 regulates breast cancer-associated alternative splicing switches

C Achour, DP Bhattarai, P Groza, ÁC Román, F Aguilo - Oncogene, 2023 - nature.com
Alternative splicing (AS) enables differential inclusion of exons from a given transcript,
thereby contributing to the transcriptome and proteome diversity. Aberrant AS patterns play …

CircSCAP interacts with SF3A3 to inhibit the malignance of non-small cell lung cancer by activating p53 signaling

D Chen, H Zhou, Z Cai, K Cai, J Liu, W Wang… - Journal of Experimental …, 2022 - Springer
Abstract Background Circular RNA (circRNA) has been recently identified as a critical
regulator during carcinogenesis. However, the biological function and potential underlying …

Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer

W Yang, L Hong, L Guo, Y Wang, X Han, B Han, Z **ng… - Cell Discovery, 2024 - nature.com
Metabolic dysregulation is prominent in triple-negative breast cancer (TNBC), yet
therapeutic strategies targeting cancer metabolism are limited. Here, utilizing multiomics …

MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors

L Urbanski, M Brugiolo, SH Park, BL Angarola… - Cell reports, 2022 - cell.com
MYC is dysregulated in> 50% of cancers, but direct targeting of MYC has been clinically
unsuccessful. Targeting downstream MYC effector pathways represents an attractive …

TDP43 promotes stemness of breast cancer stem cells through CD44 variant splicing isoforms

L Guo, H Ke, H Zhang, L Zou, Q Yang, X Lu… - Cell death & …, 2022 - nature.com
Alternative splicing (AS) is a promising clinical target for cancer treatment at the post-
transcriptional level. We previously identified a unique AS profile in triple-negative breast …

Bento: a toolkit for subcellular analysis of spatial transcriptomics data

CK Mah, N Ahmed, NA Lopez, DC Lam, A Pong… - Genome Biology, 2024 - Springer
The spatial organization of molecules in a cell is essential for their functions. While current
methods focus on discerning tissue architecture, cell–cell interactions, and spatial …

In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors

A Aktas Samur, M Fulciniti, H Avet-Loiseau… - Blood Cancer …, 2022 - nature.com
Splicing changes are common in cancer and are associated with dysregulated splicing
factors. Here, we analyzed RNA-seq data from 323 newly diagnosed multiple myeloma …